Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

By afschroeder • September 11, 2025

Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan E, Steri V, Porten SP, Koshkin VS, Friedlander TW, Feng FY, Lee JK, Wiita AP, Chu CE, Chou J. Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun. 2025 Sep 10;16(1):8215. doi: 10.1038/s41467-025-62710-0. PMID: 40931013.

Tags: Hematology/Oncology, Publications

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Powles T, Grande E, Simone G, Gómez de Liaño A, Maruzzo M, Velho PI, Kikuchi E, Vu TQ, Popovic L, Çil T, Gravis G, Radkowski[...]

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M,[...]

Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review

Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review.[...]